Harpreet Singh, MD, former FDA director, discusses the FDA's new draft guidance on radiopharmaceutical dosing and its relation to Project Optimus. In an interview with Targeted Oncology, Harpreet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback